Paper378754
Treatment of cirrhosis with colchicine. A double-blind randomized trial.
Kershenobich D and 5 others. Gastroenterology, 1979. Cited by 135 papers, by iCite.
Cite this record
ConductScience Library. Treatment of cirrhosis with colchicine. A double-blind randomized trial. Papers, record 378754. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/378754
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Colchicine | Major topic |
| Liver Cirrhosis | Major topic |
| Adult | |
| Aged | |
| Alkaline Phosphatase | |
| Clinical Trials as Topic | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Liver | |
| Male | |
| Middle Aged | |
| Placebos | |
| Proline | |
| Prospective Studies | |
| Serum Albumin |
Source PubMed
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 135 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39927511 | Colchicine for the primary prevention of cardiovascular events. | Cochrane Database Syst Rev | 2025 | https://conductscience.org/library/papers/39927511 | PubMed |
| 32054504 | Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. | Arthritis Res Ther | 2020 | https://conductscience.org/library/papers/32054504 | PubMed |
| 28381952 | The Treatment of Hepatic Fibrosis: Reversal of the Underlying Disease Process. | Gastroenterol Hepatol (N Y) | 2006 | https://conductscience.org/library/papers/28381952 | PubMed |
| 26816301 | Colchicine for prevention of cardiovascular events. | Cochrane Database Syst Rev | 2016 | https://conductscience.org/library/papers/26816301 | PubMed |
| 25278689 | Alcoholic liver disease: treatment. | World J Gastroenterol | 2014 | https://conductscience.org/library/papers/25278689 | PubMed |
| 24133661 | KASL clinical practice guidelines: management of alcoholic liver disease. | Clin Mol Hepatol | 2013 | https://conductscience.org/library/papers/24133661 | PubMed |
| 18985799 | Role of cannabinoids in chronic liver diseases. | World J Gastroenterol | 2008 | https://conductscience.org/library/papers/18985799 | PubMed |
| 15846629 | Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. | Cochrane Database Syst Rev | 2005 | https://conductscience.org/library/papers/15846629 | PubMed |
| 9046020 | Effect of chronic colchicine administration on the myocardium of the aging spontaneously hypertensive rat. | Mol Cell Biochem | 1997 | https://conductscience.org/library/papers/9046020 | PubMed |
| 8375627 | Hepatic fibrosis--current concepts of pathogenesis and therapy. | Gastroenterol Jpn | 1993 | https://conductscience.org/library/papers/8375627 | PubMed |
| 8244117 | Reversal of carbon tetrachloride induced changes in microviscosity and lipid composition of liver plasma membrane by colchicine in rats. | Gut | 1993 | https://conductscience.org/library/papers/8244117 | PubMed |
| 7038110 | A new look at cirrhosis. | J R Coll Physicians Lond | 1982 | https://conductscience.org/library/papers/7038110 | PubMed |
| 6235989 | In vitro correction of a deficiency of Con A-induced suppressor cell function in primary biliary cirrhosis by a pharmacological concentration of colchicine. | Clin Exp Immunol | 1984 | https://conductscience.org/library/papers/6235989 | PubMed |
| 6225583 | Effect of colchicine on immunoregulatory abnormalities in familial Mediterranean fever. | Clin Exp Immunol | 1983 | https://conductscience.org/library/papers/6225583 | PubMed |
| 6217006 | Correction of a suppressor cell deficiency in four patients with familial Mediterranean fever by in vitro or in vivo colchicine. | Clin Exp Immunol | 1982 | https://conductscience.org/library/papers/6217006 | PubMed |
| 6129179 | Treatment of alcohol-related liver disease with thioctic acid: a six month randomised double-blind trial. | Gut | 1982 | https://conductscience.org/library/papers/6129179 | PubMed |
| 4044871 | Structural aspects of the liver in patients with biliary disease and portal hypertension. | J Clin Pathol | 1985 | https://conductscience.org/library/papers/4044871 | PubMed |
| 3781173 | Effects of antifibrotic substances on pancreatic fibrosis following acute necrotizing pancreatitis. | Gastroenterol Jpn | 1986 | https://conductscience.org/library/papers/3781173 | PubMed |
| 2375835 | Accidental overdose of insufflated colchicine. | Drug Saf | 1990 | https://conductscience.org/library/papers/2375835 | PubMed |
| 2081478 | Interaction of alcohol with other drugs and nutrients. Implication for the therapy of alcoholic liver disease. | Drugs | 1990 | https://conductscience.org/library/papers/2081478 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/378754
GET https://conductscience.org/api/papers/v1/378754/cited_by?page=2